Literature DB >> 12629207

The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.

Hai Xiao1, Yong Mao, Shyamal D Desai, Nai Zhou, Chun-Yuan Ting, Jaulang Hwang, Leroy F Liu.   

Abstract

It has been proposed that the topoisomerase II (TOP2)beta-DNA covalent complex arrests transcription and triggers 26S proteasome-mediated degradation of TOP2beta. It is unclear whether the initial trigger for proteasomal degradation is due to DNA damage or transcriptional arrest. In the current study we show that the TOP2 catalytic inhibitor 4,4-(2,3-butanediyl)-bis(2,6-piperazinedione) (ICRF-193), which traps TOP2 into a circular clamp rather than the TOP2-DNA covalent complex, can also arrest transcription. Arrest of transcription, which is TOP2beta-dependent, is accompanied by proteasomal degradation of TOP2beta. Different from TOP2 poisons and other DNA-damaging agents, ICRF-193 did not induce proteasomal degradation of the large subunit of RNA polymerase II. These results suggest that proteasomal degradation of TOP2beta induced by the TOP2-DNA covalent complex or the TOP2 circular clamp is due to transcriptional arrest but not DNA damage. By contrast, degradation of the large subunit of RNA polymerase II is due to a DNA-damage signal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629207      PMCID: PMC152276          DOI: 10.1073/pnas.0736401100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Atp-bound topoisomerase ii as a target for antitumor drugs.

Authors:  H Wang; Y Mao; N Zhou; T Hu; T S Hsieh; L F Liu
Journal:  J Biol Chem       Date:  2001-02-23       Impact factor: 5.157

Review 2.  Tumor cell death induced by topoisomerase-targeting drugs.

Authors:  T K Li; L F Liu
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

3.  Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193.

Authors:  S K Morris; C L Baird; J E Lindsley
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

4.  Involvement of DNA topoisomerase IIbeta in neuronal differentiation.

Authors:  K Tsutsui; K Tsutsui; K Sano; A Kikuchi; A Tokunaga
Journal:  J Biol Chem       Date:  2000-12-05       Impact factor: 5.157

5.  A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.

Authors:  L H Jensen; K C Nitiss; A Rose; J Dong; J Zhou; T Hu; N Osheroff; P B Jensen; M Sehested; J L Nitiss
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

6.  Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.

Authors:  F Errington; E Willmore; M J Tilby; L Li; G Li; W Li; B C Baguley; C A Austin
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

Review 7.  The 26S proteasome: ubiquitin-mediated proteolysis in the tunnel.

Authors:  A L Kierszenbaum
Journal:  Mol Reprod Dev       Date:  2000-10       Impact factor: 2.609

8.  RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells.

Authors:  R H te Poele; A L Okorokov; S P Joel
Journal:  Oncogene       Date:  1999-10-14       Impact factor: 9.867

9.  SUMO-1 conjugation to human DNA topoisomerase II isozymes.

Authors:  Y Mao; S D Desai; L F Liu
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

10.  The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.

Authors:  B B Hasinoff; M E Abram; N Barnabé; T Khélifa; W P Allan; J C Yalowich
Journal:  Mol Pharmacol       Date:  2001-03       Impact factor: 4.436

View more
  39 in total

Review 1.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

2.  The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.

Authors:  Hai Xiao; David W Goodrich
Journal:  Oncogene       Date:  2005-12-08       Impact factor: 9.867

Review 3.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

4.  Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.

Authors:  J J Bower; G F Karaca; Y Zhou; D A Simpson; M Cordeiro-Stone; W K Kaufmann
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

5.  The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.

Authors:  Omari J Bandele; Neil Osheroff
Journal:  Biochemistry       Date:  2008-10-16       Impact factor: 3.162

6.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Authors:  Joel G Turner; Douglas C Marchion; Jana L Dawson; Michael F Emmons; Lori A Hazlehurst; Peter Washausen; Daniel M Sullivan
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

7.  Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.

Authors:  Ren-Kuo Lin; Chia-Wen Ho; Leroy F Liu; Yi Lisa Lyu
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

8.  NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.

Authors:  Jessica N Nichol; Matthew D Galbraith; Claudia L Kleinman; Joaquín M Espinosa; Wilson H Miller
Journal:  Cell Rep       Date:  2016-03-17       Impact factor: 9.423

9.  Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death.

Authors:  Bo Tian; Qian Yang; Zixu Mao
Journal:  Nat Cell Biol       Date:  2009-01-18       Impact factor: 28.824

10.  The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.

Authors:  Iris Alchanati; Carmit Teicher; Galit Cohen; Vivian Shemesh; Haim M Barr; Philippe Nakache; Danny Ben-Avraham; Anna Idelevich; Itzchak Angel; Nurit Livnah; Shmuel Tuvia; Yuval Reiss; Daniel Taglicht; Omri Erez
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.